Last reviewed · How we verify
NCT05314413
Examining Sex-based Differences in Metabolic and Mechanistic Responses to Disuse Induced Muscle Atrophy
NA trial testing Single Leg Immobilization in Muscle Atrophy in 24 participants. Completed in 15 November 2024.
15 November 2024
Quick facts
| Lead sponsor | McGill University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 1 November 2022 |
| Primary completion | 15 November 2024 |
| Estimated completion | 15 November 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Single Leg Immobilization
Conditions studied
- Muscle Atrophy — all drugs for Muscle Atrophy →
- Muscle Disuse Atrophy — all drugs for Muscle Disuse Atrophy →
Sponsor
McGill University
Who can join
Adults 18 to 35, any sex, with Muscle Atrophy or Muscle Disuse Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the proposed research is to define whether there are differences between females and males (i.e. sex-based differences) in the metabolic and mechanistic regulation of disuse-induced muscle atrophy in vivo in humans.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05314413
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscle Atrophy
Currently open trials in the same condition.
- NCT06631053 — FIT Exercise in 30d of ULLS-induced Muscle Disuse · NA · recruiting
- NCT06253104 — Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure · recruiting
- NCT06238609 — Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome · NA · active not recruiting
- NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
- NCT05627440 — A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure · NA · recruiting
Other McGill University trials
Trials by the same sponsor.
- NCT07178535 — Feasibility of Real-Time Visual Feedback in Augmented Reality to Reduce Gait Asymmetry Post-Stroke · NA · not yet recruiting
- NCT07445841 — Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training · NA · recruiting
- NCT07447830 — The Pain Reduction Using Immersive Virtual Reality During Wound Care Evaluation Study at Maimonides (PRISM) - Pilot Stud · NA · recruiting
- NCT07497425 — Neuroimmune Responses to Exercise in Chronic Back Pain · NA · recruiting
- NCT06994559 — Music as an Adjunct to Ketamine Therapy for Chronic Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05314413 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McGill University
- Last refreshed: 25 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05314413.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing